Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 3/20 | 0.45 |
| ▸ | CA2 | P00918 | 3/20 | 0.45 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.44 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TYR | P14679 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MITF | O75030 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16266071 | 0.82 | NPC1 (0.41) | BCHEACHELMNATRPV1 | |
| SCHEMBL8355093 | 0.82 | SHBG (0.55) | BCHEACHE | |
| SCHEMBL8474031 | 0.82 | CA2 (0.41) | CA1CA2TP53TSHR | |
| SCHEMBL2376809 | 0.81 | ALDH1A1 (0.47) | BCHEACHEALDH1A1CA1CA2 | |
| SCHEMBL29001421 | 0.80 | GRIA4 (0.50) | ALDH1A1CA1CA2GRIA4LMNA | |
| SCHEMBL28421458 | 0.80 | HSD11B1 (0.53) | — | |
| SCHEMBL27767638 | 0.80 | KIF11 (0.40) | BCHEACHEALDH1A1CA1CA2 | |
| SCHEMBL496716 | 0.79 | KIF11 (0.59) | BCHEACHECA1CA2 | |
| SCHEMBL4454189 | 0.79 | KIF11 (0.59) | BCHEACHEALDH1A1CA1CA2 | |
| SCHEMBL29164346 | 0.79 | FAAH (0.54) | BCHEACHEALDH1A1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2490291-B1 | LITHIUM SECONDARY BATTERY, AND NON-AQUEOUS ELECTROLYTIC SOLUTION FOR USE IN THE LITHIUM SECONDARY BATTERY | UBE INDUSTRIES (JP) | 2014-12-03 | — | — | EP | claimed |
| EP-2578577-A1 | Sulfonyl esters of tetrahydrocannabinol and derivatives thereof | Albany Molecular Research, Inc. (US) | 2013-04-10 | — | — | EP | claimed |
| US-7674922-B2 | Process for production of delta-9-tetrahydrocannabinol | ALBANY MOLECULAR RESEARCH, INC. (US) | 2010-03-09 | — | — | US | claimed |
| EP-1928853-A2 | PROCESS FOR PRODUCTION OF DELTA-9-TETRAHYDROCANNABINOL | AMR Technology, Inc. (US) | 2008-06-11 | — | — | EP | claimed |
| US-20070093665-A1 | Process for production of delta-9- tetrahydrocannabinol | AMR TECHNOLOGY, INC. (US) | 2007-04-26 | — | — | US | claimed |
| WO-2007041167-A2 | PROCESS FOR PRODUCTION OF DELTA-9-TETRAHYDROCANNABINOL | AMR TECHNOLOGY, INC. (US) | 2007-04-12 | — | — | WO | claimed |
| US-12159967-B2 | Nonaqueous electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-12-03 | — | — | US | disclosed |
| EP-4030524-B1 | NONAQUEOUS ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEM CORP (JP) | 2024-02-07 | — | — | EP | disclosed |
| EP-4318719-A2 | NONAQUEOUS ELECTROLYTE SECONDARY BATTERY | Mitsubishi Chemical Corporation (JP) | 2024-02-07 | — | — | EP | disclosed |
| US-20230343990-A1 | NONAQUEOUS ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2023-10-26 | — | — | US | disclosed |
| US-11784342-B2 | Nonaqueous electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2023-10-10 | — | — | US | disclosed |
| US-11535647-B2 | Peptide purification method using sulfonate compound | NAGASE & CO., LTD. (JP) | 2022-12-27 | — | — | US | disclosed |
| US-20220384840-A1 | NONAQUEOUS ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2022-12-01 | — | — | US | disclosed |
| US-8106244-B2 | Process for production of delta-9-tetrahydrocannabinol | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-20110263878-A1 | PROCESS FOR PRODUCTION OF DELTA-9-TETRAHYDROCANNABINOL | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-20100069651-A1 | PROCESS FOR PRODUCTION OF DELTA-9-TETRAHYDROCANNABINOL | ALBANY MOLECULAR RESEARCH, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| US-7674922-B2 | Process for production of delta-9-tetrahydrocannabinol | ALBANY MOLECULAR RESEARCH, INC. (US) | 2010-03-09 | — | — | US | disclosed |
| EP-1928853-A2 | PROCESS FOR PRODUCTION OF DELTA-9-TETRAHYDROCANNABINOL | AMR Technology, Inc. (US) | 2008-06-11 | — | — | EP | disclosed |
| US-20070093665-A1 | Process for production of delta-9- tetrahydrocannabinol | AMR TECHNOLOGY, INC. (US) | 2007-04-26 | — | — | US | disclosed |
| WO-2007041167-A2 | PROCESS FOR PRODUCTION OF DELTA-9-TETRAHYDROCANNABINOL | AMR TECHNOLOGY, INC. (US) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069651-A1 | PROCESS FOR PRODUCTION OF DELTA-9-TETRAHYDROCANNABINOL | CNR2, CNR1, HRH4 | BCHE 1254/4885ACHE 1893/4885ALDH1A1 2849/4885 |
| US-20070093665-A1 | Process for production of delta-9- tetrahydrocannabinol | CNR2, CNR1, HRH4 | BCHE 1254/4885ACHE 1893/4885ALDH1A1 2849/4885 |
| US-20110263878-A1 | PROCESS FOR PRODUCTION OF DELTA-9-TETRAHYDROCANNABINOL | CNR2, CNR1, HRH4 | BCHE 1254/4885ACHE 1893/4885ALDH1A1 2849/4885 |
| US-11535647-B2 | Peptide purification method using sulfonate compound | VIP, IAPP, RPS27A | BCHE 2289/4885ACHE 4240/4885ALDH1A1 4729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.